Rat's Rant: What's hot, what's not and ... more biotech winners
Archived
Oct 3, 2019
|
7 min
Immuron’s (ASX:IMC) second clinical-stage asset, IMM-529, targets Clostridium difficile Infections (CDI), and is presently in a clinical trial in CDI patients.
